ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
123.906,55
-0,32%
S&P 500
5.460,48
-0,41%
US Dollar vs BRL
5,5936
0,00%
Bitcoin
60.973,29
1,10%
Brent Oil
84,85
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. COMPASS Pathways PLC (CMPS)

  7. COMPASS Pathways PLC (CMPS) Notícias

CMPS

COMPASS Pathways (CMPS)

COMPASS Pathways PLC
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CMPS
DataHoraFonteTítuloCódigoCompanhia
26/06/202407:30GlobeNewswire Inc.Compass Pathways appoints Lori Englebert as Chief Commercial OfficerNASDAQ:CMPSCOMPASS Pathways PLC
22/05/202417:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CMPSCOMPASS Pathways PLC
09/05/202418:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CMPSCOMPASS Pathways PLC
08/05/202407:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CMPSCOMPASS Pathways PLC
08/05/202407:45GlobeNewswire Inc.Compass Pathways Announces First Quarter 2024 Financial Results and Business HighlightsNASDAQ:CMPSCOMPASS Pathways PLC
08/05/202407:30GlobeNewswire Inc.Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorderNASDAQ:CMPSCOMPASS Pathways PLC
02/05/202407:30GlobeNewswire Inc.Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatmentNASDAQ:CMPSCOMPASS Pathways PLC
29/04/202407:30GlobeNewswire Inc.Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depressionNASDAQ:CMPSCOMPASS Pathways PLC
28/03/202409:00GlobeNewswire Inc.Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of DirectorsNASDAQ:CMPSCOMPASS Pathways PLC
05/03/202419:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CMPSCOMPASS Pathways PLC
29/02/202409:00GlobeNewswire Inc.Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights NASDAQ:CMPSCOMPASS Pathways PLC
29/02/202408:59Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CMPSCOMPASS Pathways PLC
14/02/202418:08Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CMPSCOMPASS Pathways PLC
16/01/202410:00GlobeNewswire Inc.Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approvedNASDAQ:CMPSCOMPASS Pathways PLC
05/01/202419:04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CMPSCOMPASS Pathways PLC
05/01/202410:00GlobeNewswire Inc.Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreementNASDAQ:CMPSCOMPASS Pathways PLC
02/01/202419:20Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CMPSCOMPASS Pathways PLC
19/12/202318:05GlobeNewswire Inc.Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorderNASDAQ:CMPSCOMPASS Pathways PLC
13/12/202319:40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CMPSCOMPASS Pathways PLC
07/12/202309:00GlobeNewswire Inc.Compass Pathways appoints Teri Loxam as Chief Financial OfficerNASDAQ:CMPSCOMPASS Pathways PLC
06/12/202318:00GlobeNewswire Inc.Study results of psilocybin treatment in bipolar II depression published in JAMA PsychiatryNASDAQ:CMPSCOMPASS Pathways PLC
15/11/202306:00GlobeNewswire Inc.Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research centerNASDAQ:CMPSCOMPASS Pathways PLC
02/11/202308:00GlobeNewswire Inc.COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:CMPSCOMPASS Pathways PLC
26/10/202309:00GlobeNewswire Inc.COMPASS Pathways announces CFO transitionNASDAQ:CMPSCOMPASS Pathways PLC
19/09/202310:14Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CMPSCOMPASS Pathways PLC
19/09/202301:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CMPSCOMPASS Pathways PLC
18/09/202317:31GlobeNewswire Inc.COMPASS Pathways appoints Daphne Karydas to its Board of DirectorsNASDAQ:CMPSCOMPASS Pathways PLC
08/09/202318:17Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CMPSCOMPASS Pathways PLC
06/09/202305:00GlobeNewswire Inc.COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depressionNASDAQ:CMPSCOMPASS Pathways PLC
24/08/202321:51Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:CMPSCOMPASS Pathways PLC
 Apresentando as notícias mais relevantes sobre:NASDAQ:CMPS

Seu Histórico Recente

BIT
P21K15
NLBNPIT21K15 20241218 6200
NASDAQ
CMPS
COMPASS Pathways
BIT
UC7A92
Unicredit Bank
LSE
10GG
Investec Bnk 25
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados